What is non-invasive neuromodulation? From clinical tools to at-home technology

For most of the last century, changing brain activity deliberately meant going somewhere to have it done. A clinic, a research lab, a practitioner, a referral.

That is changing, unevenly and with some justified caution. Some neuromodulation technologies belong firmly in clinical hands and always will. Others are genuinely suited to home use. Telling the difference is the useful skill, and this article is a map of it.

What neuromodulation means

Neuromodulation is the deliberate alteration of nervous system activity using a targeted stimulus. That stimulus can be electrical, magnetic, chemical, or sensory.

The category is broad. At one end it includes implanted devices such as deep brain stimulators, used under specialist supervision for specific neurological conditions. At the other it includes non-contact sensory approaches that require no clinician at all.

Non-invasive neuromodulation refers to the subset that does not require surgery or implantation. It is a wide field with very different levels of evidence, regulation, and risk inside it, which is exactly why lumping it together is unhelpful.

How non-invasive neuromodulation developed

The thread runs further back than most people expect. Human brain activity became recordable in 1929, when Hans Berger published the first human electroencephalogram. Once you can measure a rhythm, the question of whether you can influence it follows quickly.

Rhythmic photic stimulation was being studied within a few decades of that. Transcranial magnetic stimulation arrived in the 1980s. Transcranial direct current stimulation in its modern form came into research use around 2000. Audiovisual stimulation developed alongside them, mostly outside mainstream clinical neuroscience, in a scattered and under-standardized literature.

What has changed recently is not the underlying science. It is the engineering and the cost.

Transcranial magnetic stimulation (TMS)

TMS uses rapidly changing magnetic fields, generated by a coil held against the scalp, to induce electrical currents in targeted regions of the cortex.

It is a regulated clinical intervention. In most jurisdictions it is delivered by trained staff in a clinical setting, over a course of sessions, for specific authorized indications. Equipment cost is substantial, sessions are supervised, and the evidence base for its authorized uses is developed and controlled.

TMS is targeted and relatively focal. It acts on a specific cortical area, which is a large part of its clinical value.

Transcranial direct current stimulation (tDCS)

tDCS delivers a weak, constant electrical current through electrodes placed on the scalp, altering the likelihood that neurons in the affected region will fire.

It appears in research, some clinical settings, and some consumer products. Its evidence base and regulatory status vary considerably by device and intended use, and it is an area where consumer availability has at times run ahead of the supporting evidence. It involves direct electrical contact with the scalp, which places it in a different risk category from non-contact approaches.

Audiovisual stimulation (AVS)

Audiovisual stimulation can be described as a form of non-invasive sensory stimulation intended to influence patterns of neural activity. It uses coordinated rhythmic light and sound rather than electricity or magnetism, and it reaches the brain through the normal sensory pathways: the eyes and the ears.

Because it does not deliver energy through the skull, it is sometimes described more precisely as sensory neuromodulation. That term is worth using, because it makes the distinction that matters. AVS is not a weaker version of TMS. It is a different thing that acts through different pathways.

Its evidence base is developing rather than established. The most current structured review of the field found the literature heterogeneous, including null and limited results, with mechanistic understanding and parameter optimization still insufficiently developed, and concluded that premature claims of efficacy are not warranted (Rahmani, Romero Lauro & Pisoni, 2025).

That is a fair description of where things stand, published by researchers working in the field. We would rather point you to it than paraphrase it into something more flattering.

Key differences between the approaches

Beyond mechanism, the practical differences are these:

• Evidence base. TMS has the most developed and controlled evidence for its authorized indications. tDCS is variable. AVS is developing, with a well-replicated mechanism and a thinner outcome literature.
• Regulation. TMS and prescription tDCS applications are regulated as medical devices. Consumer AVS products are wellness products and make no medical claims.
• Intended use. Clinical technologies address diagnosed conditions. Consumer sensory stimulation addresses everyday states such as winding down or preparing to concentrate.
• Supervision. TMS requires trained personnel. AVS does not.
• Cost and accessibility. Clinical courses of treatment run into thousands. Consumer devices are a one-time purchase.
• Suitability for home use. Non-contact sensory stimulation is far better suited to unsupervised daily use than approaches that deliver current or magnetic energy to the head.

AVS should not be presented as medically equivalent to TMS or tDCS, and we do not present it that way. Different mechanism, different evidence base, different regulatory status, different purpose.

The accessibility gap

Between the clinic and the consumer market there has been very little.

If you have a diagnosed condition, there are regulated pathways with trained people at the end of them. If you simply want to wind down reliably before an important morning, or come down after a demanding day, the options have been meditation, medication, or nothing.

That gap is not a gap in the science. Rhythmic sensory stimulation has been studied for decades. It is a gap in delivery: what existed was either clinical, supervised, and expensive, or unstructured and unmeasured. Very little sat in between, built to a real standard and designed to be used by an ordinary person on a Tuesday night.

Consumer sensory stimulation is one attempt at filling that space. Whether it fills it well is a question about specific devices, specific protocols, and specific evidence, and it should be asked device by device rather than answered for the category.

Why accessibility and repeatability matter

A home-use format can make it easier for people to incorporate sessions into a consistent routine. However, any claims about the benefits of repeated use should be supported by evidence for the specific device and protocol.

That second sentence is the important one, and it applies to us as much as to anyone. Regular use of something you own is more practical than periodic use of something you have to travel to. Whether regular use produces cumulative benefit is a separate empirical question, and it is not one a consumer device should assert without its own data.

What accessibility genuinely changes is the relationship. A clinical intervention is something done to you on a schedule set by someone else. A home instrument is something you reach for when you decide to. That is a difference in agency, which is a fair thing to describe, and it is not the same as a difference in clinical outcome.

How Domayn approaches sensory stimulation

Domayn applies audiovisual stimulation through coordinated light and sound delivered using a mask and headphones, with protocols designed around four moments in a day: Wake, Focus, Relax, and Sleep. Sessions run five to fifteen minutes.

The positioning is deliberately narrow. The Mask is a consumer wellness product, not a medical device, and it is not intended to diagnose, treat, cure, or prevent any disease or medical condition. It makes no clinical claims and is not an alternative to medical treatment. It does not read your physiology, and it sits alongside the tracker you already wear rather than replacing it.

It is also not suitable for everyone. The Mask is not suitable for people with photosensitive epilepsy or a history of seizures triggered by flashing lights. As with any light-based device, a small number of users may experience mild, temporary discomfort including headache or eye strain. If you experience any adverse symptoms during or after use, discontinue use and consult a healthcare professional. If you have a medical condition, are pregnant, or are taking medication, consult your healthcare provider before use.

read what the science does and does not support

Where the field goes

The future of non-invasive brain stimulation may include a wider range of personalised and accessible tools. The challenge will be ensuring that convenience is matched by responsible design, credible evidence, and clear communication about what each technology can and cannot do.

The last of those three is the one most likely to be neglected, and it is the cheapest to get right. A company that is precise about the limits of its evidence is easier to trust on everything else.

Feel Different.

Frequently asked questions

What is non-invasive neuromodulation?

Non-invasive neuromodulation is the deliberate alteration of nervous system activity using a stimulus applied from outside the body, without surgery or implantation. It includes magnetic, electrical, and sensory approaches.

What is the difference between TMS, tDCS, and AVS?

TMS uses magnetic pulses to stimulate targeted brain regions and is a regulated clinical intervention. tDCS passes a weak electrical current through scalp electrodes, with evidence and regulation varying by device. AVS uses coordinated rhythmic light and sound, reaching the brain through normal sensory pathways rather than delivering energy through the skull.

Can neuromodulation be used at home?

Some forms can. Non-contact sensory approaches such as AVS are well suited to unsupervised home use. Clinical technologies such as TMS require trained personnel and a clinical setting.

Is AVS a type of neuromodulation?

Yes, though it is most precisely described as sensory neuromodulation, because it influences neural activity through the eyes and ears rather than by applying current or magnetic fields to the head.

How are consumer neurotechnology devices regulated?

It depends on the claims a device makes. A device presented as treating a condition sits in a different regulatory category from one sold as a consumer wellness product, which makes no medical claims. The distinction is worth checking on any product you consider, because the language on a product page does not always make it obvious.

References

1. Berger, H. (1929). Über das Elektrenkephalogramm des Menschen. Archiv für Psychiatrie und Nervenkrankheiten, 87, 527–570.
2. Rahmani, M., Romero Lauro, L. J., & Pisoni, A. (2025). Audio-Visual Entrainment Neuromodulation: A Review of Technical and Functional Aspects. Brain Sciences, 15(10), 1070. doi.org/10.3390/brainsci15101070
3. Herrmann, C. S. (2001). Human EEG responses to 1–100 Hz flicker. Experimental Brain Research, 137(3–4), 346–353. doi.org/10.1007/s002210100682